Recap: NeoGenomics Q2 Earnings

Shares of NeoGenomics NEO rose 1% after the company reported Q2 results.

Quarterly Results

Earnings per share fell 157.14% over the past year to ($0.04), which beat the estimate of ($0.10).

Revenue of $86,977,000 decreased by 14.49% from the same period last year, which beat the estimate of $86,120,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Jul 28, 2020

Time: 08:30 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1219/35578

Price Action

52-week high: $37.70

52-week low: $18.52

Price action over last quarter: Up 18.70%

Company Overview

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.